Enlivex (ENLV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enlivex Therapeutics Ltd. has initiated a pivotal Phase I/II trial for Allocetra, marking a significant stride in potentially treating thumb osteoarthritis, a condition with no current FDA-approved treatments. The trial will evaluate the safety and effectiveness of Allocetra injections in patients who have not responded to conventional therapies, with plans to enroll up to 46 participants. Enlivex’s Allocetra therapy aims to restore macrophage homeostasis, offering a novel approach to treating a variety of severe and debilitating diseases.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.